home > events calendar > more about event

14th Annual Biomarkers Congress

Biomarkers Congress UK 2019

21-22 February 2019
Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.

Biomarkers are a fundamental part of drug development, playing a critical role in drug discovery, preclinical and clinical development, diagnostics and prognostics. Across two days and over 55 presentations, senior experts will provide a comprehensive look at the marketplace to make sure you leave with an increased knowledge of the current trends influencing biomarker research. 

2019 sees the return of our popular discovery, precision medicine and clinical streams designed to provide updates across multiple therapeutic areas, from market-dominating oncology and neuroscience through to more emerging fields such as infectious, cardiovascular and rare diseases. Benefit further from case studies on topical technology innovation in this space: imaging techniques, proteomics and immuno-assays. We are also pleased to announce an additional two streams highlighting important opportunities in the biomarker market: Biomarkers for Early Detection and Prognosis and Digital Biomarkers.

Key Speakers include:

Mark Fidock, Vice President, AstraZeneca 

Frank Kramer, Director Biomarker Strategist, Bayer 

Thomas Hach, Director Healthcare Systems, Novartis 

Devangi Mehta, Director, Development Biomarkers and Bioanalytical Sciences, Biogen 

Kay-Gunnar Stubenrauch, Head of Large Molecule Bioanalytical Sciences 1, Roche 

Joanne Hackett, Chief Commercial Officer, Genomics England

The two day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions from panels and roundtables through to two workshops on clinical biomarker assay validation and data analytics.  It brings together over 350 senior industry experts and key opinion leaders in biomarkers. For more information about the programme and registration, please contact Angela Fernandez Saez at

Contact Details: 

General Enquiries: +44 (0) 1865 248455

For speaker opportunities contact
For sponsorship opportunities contact
For information on registration contact
For press & marketing enquiries contact

phone +44 1865 248 455
email Manchester, UK
Print this page
Send to a friend
Industry Events


28-30 April 2020, Javits Center NYC

More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement